ContraFect to Host Development Update Call and Webcast on October 2, 2019
October 01, 2019 17:29 ET
|
ContraFect Corporation
YONKERS, N.Y., Oct. 01, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect to Present New Exebacase Data Including a Late Breaker Oral Presentation on the Reduction in Health Resource Utilization Among Exebacase-Treated MRSA Patients in the Recently Completed Phase 2 Study at IDWeek 2019
September 26, 2019 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 26, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect to Present at the 2019 Janney Healthcare Conference
September 04, 2019 17:07 ET
|
ContraFect Corporation
YONKERS, New York, Sept. 04, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Announces Presentation of New Data from its Amurin Peptide Program at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
August 28, 2019 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Aug. 28, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Reports Second Quarter 2019 Financial Results and Provides Business Update
August 09, 2019 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Aug. 09, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Disease
May 08, 2019 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., May 08, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...